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Abstract:
Fleischer, Justin Caveolin Binding Motif Mutation Yields a Variance in Follicle Stimulating
Hormone Receptor Signaling
Advisor: Brian D. Cohen
The human follicle stimulating hormone receptor (hFSHR) is a glycoprotein
hormone receptor belonging to the g protein-coupled receptor family. It is important in
both male and female reproductive processes; defects in hFSHR can lead to infertility,
delayed puberty, reduced muscle bulk, and osteoporosis. Work in other labs has shown
that GPCRs can be localized to microdomains located within the cell membrane called lipid
rafts. These regions are highly resistant to detergents because of the high concentration of
sphingolipids and cholesterol. Also within these domains, an intracellular protein, caveolin,
is present. Our lab has shown that hFSHR also localizes to lipid raft domains. We
hypothesize that interaction with caveolin is important in the raft residency of hFSHR
through a putative caveolin binding motif (CBM). The interaction between caveolin and
hFSHR in these microdomains may regulate intracellular pathways activated by the
receptor.
To test our hypothesis, we have constructed CBM mutants and are in the process of
creating stable cell lines expressing the mutant receptors to study the effects of mutating
the key phenylalanine residues of the CBM. Interestingly, wild type FSHR presents as a
doublet on a western blot while the 479L only have a single band. We theorize that one of
these bands may be a glycosylation variant however further investigation is required. The
mutated receptors qualitatively show normal p44-MAPK signaling in response to FSH,
indicating that they are reaching the cell surface and are capable of binding hormone and
coupling to signaling partners. We have observed a subtle difference in downstream PKA
targets between the mutant and wild type hFSHR, suggesting that there might be a
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difference in the ability to activate downstream targets. Studying the interaction between
hFSHR and caveolin has the potential to develop new contraceptive antagonists and
alternative agonists to regulate fertility.
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Introduction:
The ability of all living organisms to receive and respond to external stimuli is
essential for survival. These processes are regulated by cell surface receptors including g
protein-coupled receptors (GPCRs). GPCRs account for over 800 types of receptors and are
the largest set of drug targets in the pharmaceutical market, thus signifying the importance
of their study in greater detail.1 The human follicle stimulating hormone receptor (hFSHR)
is a glycoprotein hormone GPCR important in both male and female reproductive
processes.2 hFSHR is expressed on the granulosa cells of the ovary in females, and the
sertoli cells of the testis in males. When activated with human follitropin from the anterior
pituitary, hFSHR induces a signal transduction pathway leading to follicular maturation in
females and sperm production in males.2
Follitropin signaling:
Follitropin is released by the gonadotrope cells of the anterior pituitary in response
to gonadotropin releasing hormone (GnRH).2 GnRH is released from the hypothalamus in
pulses based on gonadal steroid signaling.3 GnRH travels through the hypophyseal portal to
the anterior pituitary stimulating the production of lutenizing hormone and follitropin.
Slow GnRH pulses stimulate the production and secretion of follitropin in gonadotrope
cells.4 Follitropin is then released into the blood stream. In order for the signal to be
received successfully, follitropin must bind successfully to its GPCR, FSHR.1
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Figure 1. Diagram Illustrating Hypogonadal Axis5

FSHR belongs to the glycoprotein family of hormone receptors (GPHRs). Similar to
other GPCRs, the protein crosses the membrane seven times as α-helices with a supersecondary structure of α-turn-α in three intracellular loops (IL) and three Extracellular
loops (EL).6

Figure 2. Human Follicle Stimulating Hormone
Receptor
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The transmembrane domain is highly conserved within the GPHR class. The
receptor has three primary domains: Ectodomain, transmembrane domain and
endodomain. The ectodomain is composed of
two significant subdomains, the hormone
binding subdomain and the signal specificity
binding domain. Within the hormone-binding
domain there are 12 lecuine rich repeats and
other hydrophobic residues giving it a
cylindrical-horseshoe shape.5 The hormonebinding domain possesses β-sheets,
complementary to follitropin, allowing it to
interact electrostatically.
The hinge region of the binding domain
contains three critical disulfide bonds that

Figure 3. Molecular structure FSHR6

communicate a conformational change through

the transmembrane domain upon the binding of follitropin. As follitropin binds to the
hormone-binding domain, a conformational change in the signal molecule is believed to
take place exposing a pocket within the follitropin. This pocket is specific for a sulfated
tyrosine that lies on the hinge region. As residues on follitropin stabilize the sulfated
tyrosine, a conformational change in the receptor occurs, which is communicated through
the transmembrane domain into the endodomain.5
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Figure 4. Signal transduction of

FSHR6

It is believed that this conformational change on the C-terminus (intracellular side)
of the GPCR causes a conformational change in the attached Gsα-subunit. This structural
change causes the subunit to favor the release of GDP and uptake of GTP, which activates
the G-protein. Gsα stimulates the activity of adenyl cyclase, which converts ATP cyclic
adenosine monophostophate (cAMP).7 cAMP then activates protein kinase A (PKA), which
phosphorylates cAMP response element binding protein (CREB). CREB is a transcription
factor that will then act to stimulate steroidogenesis, which is involved in the
aforementioned processes of sex cell maturation.

Figure 5. Downstream signaling of FSHR

There are many components within the plasma membrane that are required for
appropriate signal transduction, and appropriate activation of secondary messengers.

9

However, these components are expressed at relatively low levels along the surface. Given
this low density, it would be nearly impossible for these components to randomly associate
at the correct time to transduce a signal. Yet somehow, this signaling occurs rapidly and
efficiently.
Plasma membrane & Lipid Rafts:
One possible mechanism for the efficient transduction of signal is that these
components co-localize in a sub-domain of the plasma membrane referred to as lipid rafts.
All cells are separated from their surroundings by a plasma membrane. This membrane is
semipermeable to certain ions, and small organic molecules, and controls the migration of
larger molecules moving in to and out of the cell. Plasma membranes are composed of a
lipid bilayer studded with various proteins. The lipid bilayer consists of hydrophobic acyl
chains with a polar head group. In an aqueous environment, the hydrophobic head groups
are exposed to the surroundings and interior of the cell, while the acyl chains lay within the
membrane itself.
Based on the fluid mosaic model, the lipid bilayer functions as a two-dimensional
liquid.8 According to this model, individual proteins and acyl chains are able to move
relatively freely within the membrane. However, there is a certain fluidity/permeability
balance that must be met for the cell to function. Because some of the acyl chains possess
double bonds, there are often openings within the membrane itself.7 The addition of
cholesterol into the plasma membrane allows these gaps to close, and limit the
permeability and fluidity of the cell. The intercalation of cholesterol at higher
concentrations can also produce micro-domains known as lipid rafts.9
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Figure 6. Intercalation of cholesterol in plasma membrane10

These sub-domains are characterized by a higher concentration of sphingolipids and
high levels of cholesterol, allowing the acyl chains to pack more densely.8 Lipid rafts are
expressed in a wide variety of cells, however, a certain subset of those cells also express the
protein, caveolin.
Caveolin:
Caveolin is a 21 kD, structural membrane protein. The presence of caveolin in the
membrane causes a 50-100 nm invagination of the lipid raft membrane, referred to as
caveolae.9 It has been demonstrated in literature that these domains enable spatial colocalization of interacting proteins to promote efficiency of signal transduction.11 Caveolae
are primarily found in muscle cells, endothelial cells, and adipocytes.
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Figure 7. Caveolin promote formation of caveolae12

There are three isoforms of caveolin found in mammalian cells, caveolin-1, caveolin2, & caveolin-3. All three proteins express a similar conformational structure with a
cytoplasmic C & N terminus with a hairpin loop transmembrane domain, however, they
differ in which tissues they are expressed in.9 For example, caveolin-3 is exclusively
expressed in skeletal and cardiac myocytes. Caveolin-1, the predominant form, tends to
dictate caveolae formation through oligomerization.
Caveolin has three major functions when it comes to the formation of lipid rafts and
signal transduction. Primarily, it is involved with forming the flask like invaginations within
the membrane of the cell. It does this by essentially reducing the physical strain caused by
the curvature of the membrane.13 Caveolin also acts as a scaffolding protein. It has the
ability to recruit specific proteins to localize within the caveolae. Finally, caveolin acts as a
protein chaperone, and assists with cell membrane trafficking. Within caveolin itself,
subdomains exist to carry out these various processes. An example of this is the scaffolding
domain of caveolin (CSD).9 This string of amino acids acts to anchor necessary signaling
molecules for efficient signal transduction. The proteins that co-localize with caveolin
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express a sequence of amino acids that interact with the CSD referred to as the caveolinbinding motif (CBM).
These short amino acid chains are
hydrophobic and rich in aromatic
residues. The typical sequences are
ϕxϕxxxxϕ or ϕxxxxϕxxϕ or combined
sequence ϕxϕxxxxϕxxϕ, where ϕ is a
phenylalanine, tyrosine or tryptophan
residue, and x can be any amino acid.14 It
has been established that hFSHR
expresses the CBM sequence of amino
acids between residues between 479 &
Figure 8. Caveolin scaffolding domain schematic15

489 with each aromatic residue being a phenylalanine.
Caveolin Binding Motif
Ф X Ф X X X X Ф X X Ф
479 481
486
489
In order to further investigate caveolin-hFSHR interactions, we have set out to
establish stable mutant cell lines that express different combinations of mutations in each
of the phenylalanine locations. Previous research in the Cohen lab has generated
transiently transfected mutants of the caveolin binding motif, but none that readily express
the mutated receptor organically. Our research represents the investigation of an F479L
polymorphism. By evaluating behavior of the mutated domain we can better understand
the relationship between hFSHR and lipid rafts. As the interaction is better comprehended,
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research can be focused on the implications of this interaction in infertility and birth
control.
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Methods:
Cell Culture:
Human Embryonic Kidney cells 293 (HEK293) were grown in culture at 37°C in DMEM
with 10% fetal bovine serum and penicillin & streptomycin. Cells were transfected with
either wild type hFSHR DNA or mutant hFSHR F479L using SatisFection.

DNA Stable Transfection:
At 75% confluence, HEK293 cells were transfected using SatisFection reagent. Cells were
then cultured in G418 antibiotic to select for lines expressing mutated (F479L) receptor or
wild type. After several days, colonies of surviving cells were collected and plated in a 96
well dish. Those that continued to proliferate were then transferred to a 12 well and then
to a 6 well, and finally transferred to a T25 and a T75 flask as they reached confluence. For
more details refer to Satisfection Transfection Reagent manual in Appendix B.

SDS-PAGE Western Blot Hormone Treatment:
Upon T75 confluence, both HEK293 WT and F479L mutant cells were treated with 2000 ng
of FSH for either zero, five, 15, or 30 minutes. The cells were then lysed and protein
contents evaluated by gel electrophoresis using 7.5% acrylamide gel. The proteins were
then transferred to a PVDF membrane using a semi-dry electrophoresis method and
blocked with 5% milk in TBST. The membranes were then probed with Anti-hFSHR mAb
106.105 (105) for hFSHR; P-p44/42 MAPK Rabbit Ab for phosphorylated p44; and P-PKA
substrates for downstream signaling targets of P-PKA. Membranes were then probed with
anti-mouse secondary antibody for 105 and anti-rabbit for P-p44 and P-PKA substrates.
Membranes were imaged (BIORAD ChemiDoc MP Imaging System). For more detailed
procedures refer to Appendix C.
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Immunofluorescence Microscopy:
HEK 293 WT and F479L mutant were grown on glass coverslips and fixed using a 4%
paraformaldehyde PBS solution. Cells were probed for hFSHR using mAb 106.105. Goat
anti-mouse with an alexa-red fluorophore was used as a secondary antibody. Slides were
then evaluated on fluorescent microscope (Olympus BX60).

Discontinuous Sucrose Gradient
2 T75s of each HEK 293 WT and F479L were grown to 80% confluence. One T75 of each
was treated with 2000 ng of FSH, incubated for 30 minutes. Cells were collected and
resuspended in 0.5 M sodium carbonate (pH 11) and incubated for 20 minutes. Cells were
then dounced and sonicated. Lysates were added to 90% sucrose in 1:1 dilution and added
to ultracentrifuge tube. A 35% solution followed by a 5% solution were laid on top.
Ultracentrifuge (Beckman L-70) was run at 34,000 RPM for 16 hours. Fractions from the
gradient were recovered and analyzed using SDS-PAGE and Western Blot. Gel
electrophoresis was carried out using 7.5% acrylamide gel. Proteins were then transferred
to a PVDF membrane using a semi-wet electrophoresis method and blocked with 5% milk
in TBST. The membranes were then probed with Anti-hFSHR mAb 106.105 (105) for
hFSHR. Membranes were then probed with anti-mouse secondary antibody for 105.
Membranes were imaged (BIORAD ChemiDoc MP Imaging System).
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Results:
Establishment of a stable hFSHR-F479L expressing cell line
After HEK293 cells were transfected with F479L SatisFection vector, colonies were
harvested and receptor expression were evaluated (See Methods: DNA Stable Transfection
for details). Colonies were then labeled A-F and evaluated using SDS-PAGE/Western Blot.
Membranes were probed with anti-hFSHR mAb 106.105 (Figure 10).

Figure 9. Figure 1. Western blot of protein lysates from HEK 293 cell lines stably transfected with hFSHR-479L
mutant (Lanes A-F). Lane WT is control HEK 293 cell line stably expressing wild type receptor. hFSHR probed
with anti-hFSHR mAb 106.105. Mutant cell line from lane E was used to carry out subsequent experiments.

There is a single band at 80 kD seen in Lanes A-F of similar intensity. There is also a darker
band in the WT lane at 80 kD along with a faint band around 50 kD mark.
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Does hFSHR-F479L Localize on the Cell Surface Similar to Wild Type Receptor?
HEK293-hFSHR F479L (Mutant) were compared to HEK293-hFSHR (WT) using
immunofluorescence.

Figure 10. Immunofluorescence of HEK 293 cells stably expressing hFSHR isoforms as indicated. A & B- Wild Type
hFSHR, C & D- hFSHR-F479L mutant.

The top row of Figure 10, labeled WT, represents the HEK293-hFSHR wild type cells and
the bottom row represents the F479L mutant. A and C represent cells that were not treated
with 106.105 antibody and serve as a negative control. In B and D there is increased
fluorescence around the perimeter of the cell indicating that both the wild type and mutant
receptor are localizing in the cell membrane.
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Does the Mutated Receptor Localize in Lipid Rafts?
To investigate the localization of the mutated receptor in lipid rafts, a discontinuous
sucrose gradient followed by SDS-PAGE Western blot was carried out (See methods for
detailed procedures). The results of the Western Blot can be seen below.

Figure 11. Figure 3. Western blot of protein lysates from HEK 293 cell lines expressing wild type hFSHR or hFSHRF479L. Cells were treated for 30 min with 20ng/ml hFSH followed by separation on a discontinuous sucrose
gradient. Collected fractions were probed for hFSHR using mAb 106.105. Lipid rafts are predicted to be seen in
fractions 5, 6, 7.

The red box indicates where the fractions from the sucrose gradient where lipid
rafts may be present. It is apparent that there is receptor present within the lipid rafts in
both the wild type and F479L mutant.
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Does a Mutation in the Caveolin Binding Motif Affect Downstream Signal Transduction?
F479L and wild type were treated with FSH for 0, 5, 15, or 30 minutes. Cells were
then lysed and analyzed via Western Blot. Membranes were then probed for
phosphorylated PKA substrates and phospho-P44 MAPK. The results of these blots can be
seen below.

Figure 12. Figure 4. Western blot of protein lysates from HEK 293 cell lines expressing wild type hFSHR or hFSHRF479L. Probed for hFSHR, p44-MAPK (top), and PKA Substrates (bottom). ★- indicates bands that are different
between the cell lines for PKA substrates

Based on the above blot probed for P44-MAPK, similar density bands can be
observed between wild type and mutant. This indicates that P44-MAPK signaling seems
to be conserved. On the other hand, there are several differences between wild type and
mutant in downstream PKA substrates. These differences are noted by stars on the right
side of Figure 12. These differences indicate that there may be slight differences in
downstream PKA signaling.
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Discussion:
There were two main phases to the experiments carried out to investigate F479L
mutant receptor. The first phase, was first to create a cell line that is stably expressing the
F479L mutation in the hFSHR. The second phase, was to investigate the raft residency,
function, and consequential/downstream signaling of the mutated receptor, and compare it
to the wild type receptor.
Previous work in our lab has investigated a transient or temporary transfection of
the F479L mutant.16 Here, we used a stable transfection method to better simulate in vivo
mechanisms. Also, by establishing a cell line that is stably expressing the F479L receptor,
future experimentation can be carried out more efficiently. After HEK293 F479L colonies
were established, cells were lysed and evaluated for presence of hFSHR using a Western
Blot. The results of this experiment can be seen in figure 9. Here it can be noted that
receptors are present in each of the mutant colonies established, as well as the wild type
cells. For the purposes of consistency, we used cell line E for future experimentation.
Within this figure, it is also important to note within the wild type lane the presence of a
second band approximately 20 kD below the receptor. It is thought that this band may be a
potential glycosylation variant of the wild type receptor. It is also important to note that
this variant is barely visible within the mutant lanes.
Past research has demonstrated that the glycosylation of hFSHR occurs at four
different sites within the extracellular domain. Although it has been shown that
glycosylation is not directly necessary for hormone binding, certain sites are required for
proper conformational folding in order for receptor to properly bind to hormone. 17
The second phase of our experiment investigated the localization and function of the
mutated receptor. First, we used immunofluorescence to establish that the receptor was
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residing within the cell membrane. The results of this experiment can be seen in Figure
10A-D. Figure 10A and 10C served as our negative control, and were therefore not treated
with primary antibody. This was done to negate any effects of auto-fluorescence or
background fluorescence. The presence of red fluorescence around the perimeter of the
cells in both the wild type and F479L mutant is indicative of the localization of receptor
within cell membrane. It is not quantifiable because this was done using indirect
immunofluorescence. However, we can conclude that receptors are present within the cell
membrane in both wild type and mutant.
It is believed, that within the cell membrane there lies a region of higher buoyancy
designated as lipid rafts. Next, we set out to examine if the mutated receptor localizes
within these domains similarly to the wild type. To do this we performed a discontinuous
sucrose gradient followed by a Western Blot analysis. The results of this experiment can be
seen in Figure 11. In the wild type analysis, receptors can be seen localizing within the lipid
raft region of the sucrose gradient indicated by the red box. However, receptors can also be
seen in later or denser fractions. There are several reasons this may be the case. As
discussed earlier, there are glycosylation variants of the wild type receptor. This
glycosylation may occur at different stages. Glycosylation can occur in the endoplasmic
reticulum and within the golgi apparatus. Enzymatic glycosylation can also occur while the
protein is being transported to the cell surface. These bands may be indicative of
"immature" receptor in different stages.
Within the F479L assay, receptor can also be seen present within the lipid raft
fractions of the sucrose gradient. However, expression is greatly reduced. Perhaps this is a
result of an interruption of the caveolin-binding motif. A disruption of this domain could
potentially disturb the co-localization with caveolin and may down regulate the amount of
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receptor localizing within lipid rafts. It is also important to note that unlike the wild type,
receptor does not seem to be present in denser sucrose fractions.
Our last experiments focused on downstream signaling of receptors to determine if
the mutation had an impact of consequential signaling. As seen in figure 5, there are two
primary signal transduction pathways that are activated as a result of FSH binding to
receptors. The first pathway we examined was the Arrestin/p44 MAPK pathway. This was
done by treating the cells with hormone for varying lengths of time, lysing the cells, and
analyzing via Western Blot. The results of this can be seen in Figure 12. First, membranes
were probed with anti-hFSHR mAb 106.105. Within the wildtype membrane it can be seen
that more receptor seems to be recruited with the addition of hormone although this
mechanism has yet to be investigated. On the other hand, this did not occur within the
mutant. The membranes were also probed with anti-phospho-p44/MAPK. Here it can be
seen that signaling seems to be conserved in the mutant relative to the wild type. Although
the amount of receptor seen at 5 and 15 minutes in the wild type increased, it is also
important to note that the expression of the secondary messenger p44/MAPK seems to be
conserved between wild type and mutant. This has also been demonstrated in the work of
Stanley Soroka '16. Although Soroka's experiments used a transient transfection technique,
it can be seen in Appendix A that p44/MAPK signaling was also conserved with the F479L
mutant. Therefore, it can be concluded that the F479L mutation does not affect the
arrestin-P44/MAPK pathway.
The other pathway that hFSHR activates is the Gsα-PKA pathway seen in Figure 5.
Here, membranes were probed with a downstream PKA substrates antibody. Unlike the
p44-MAPK pathway, it seems there are slight variations in downstream signaling within
this pathway. One potential mechanism for this could be the idea that free caveolin-1
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within the cell can inhibit PKA signaling. Expression of activated CREB was noted to
drastically decrease with presence of cav-1 in vitro.17 Therefore, by disrupting the CBMCSD interaction, more caveolin may be present within the cytoplasm yielding down
regulation of PKA substrate activation. On the other hand, although it has been shown that
caveolin also interacts with MAPK, there did not seem to be a difference in signaling in our
experiments.
For future investigation it would be important to examine certain components of the
experiments carried out here. For example, these experiments were done under the
assumption that a mutation within the transmembrane domain of the receptor will not
affect the hormone-binding region. Therefore, we assumed that hormone would bind
equally between the wild type receptor and mutated receptor. If untrue, this would result
in altered consequential signaling between receptors. Another assumption made for this
study was that the levels of caveolin-1 and caveolin-2 in HEK293 cells are similar to that of
Sertoli or granulosa cells. Because caveolin plays such a dynamic role in the localization of
hFSHR and its downstream elements, lower or higher levels of caveolin could drastically
change this dynamic, and consequentially affect results seen here. Furthermore, caveolin
expression and co-localization with receptor should also be investigated to determine if
there is decreased co-localization with the mutated receptor. This could be done using
immunofluorescence or discontinuous sucrose gradient assay followed by Western Blot
analysis. Effects of F481L, F486L, and F489L mutations should also be investigated. Based
on previous work, it has been established that the F481 lies in an opposite direction of the
other aromatic residues as seen in Figure 13.
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Figure 13. A view of transmembrane domain IV, the caveolin binding motif, of hFSHR. Demonstrates the alpha
helix from intracellular to extracellular domain.

On the other hand, F479, F481, and F486 come before the P487 residue, which
interrupts the helix. In this case, the F489 residue may have the least effect on the CBM-CSD
interaction. Further experimentation is required to elucidate the dimensional mechanisms
of the CBM-CSD interaction. Once these single mutations have been investigated,
combinations of these mutations should be examined to determine if any of them have a
greater role in the disruption of this interaction.
Disruption of the interaction of caveolin with hFSHR could potentially interrupt
reproductive signals of the HPG axis. By interrupting these signals without impacting
hormone levels, contraception could be achieved without the negative implications of birth
control.
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Appendix A: Soroka '16 Western Blot of transient transfected hFSHR variants

105
WT 479 481 486 489
0 min FSH

5 min FSH

15 min FSH

Total
p38 481 486 489
WT 479

pp44
WT 479 481 486 489

27

Appendix B: Satisfection Transfection Reagent

SatisFection Transfection Reagent
MATERIALS PROVIDED
Quantity
Materials provided
SatisFection Transfection Reagent
a

a

Catalog #204121

Catalog #204122

Catalog #204123

0.3 ml

0.75 ml

2 × 0.75 ml

The reagent has been optimized for 625–1250 transfections per 0.75 ml transfection reagent using 24-well
tissue culture dishes.

STORAGE CONDITIONS
SatisFection Transfection Reagent: 4°C

ADDITIONAL MATERIALS REQUIRED
Media for preparing transfection mixture (Opti-MEM, DMEM, RPMI or other cell culture media
without serum and antibiotics)
Media for cell growth (Opti-MEM, DMEM, RPMI, or other cell culture media, including serum,
growth factors, and antibiotics if appropriate)

Revision B

© Agilent Technologies, Inc. 2010.
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INTRODUCTION
Gene transfection into eukaryotic cells is a fundamental tool for analysis of
gene function and for production of recombinant gene products.
SatisFection Transfection Reagent gives optimal efficiencies and protein
expression levels in common cell lines, while significantly improving
efficiencies in many hard-to-transfect and primary cells. Maximum gene
expression and protein production is observed 36–72 hours posttransfection.
The SatisFection reagent is a novel cationic polymer suitable for both
transient and stable transfections in the presence or absence of serum. This
polymer functions by binding and condensing DNA into a polyplex that
enters the cell via endocytosis. Properties of the polyplex facilitate both
endosomal rupture and protection of the bound DNA from lysosomal
degradation. Continued exposure to cellular pH ultimately reduces the
polymer into a non-toxic monomer. The monomer is then easily excreted
from the cellular compartment, resulting in lowest the levels of cytotoxicity
and increased cell viability. As a result, the SatisFection reagent is ideal for
experiments that require large, healthy populations of positively transfected
cells for downstream applications, e.g., signal transduction pathway
analysis.

PREPROTOCOL CONSIDERATIONS
The protocol provided below will allow effective transfections for most cell
types, however, optimal transfection conditions may vary. The following
parameters should be established for each cell line and plasmid used.

DNA Quality and Concentration
The use of highly purified DNA is critical for successful transfection.
Suitable quality DNA is obtained using StrataPrep plasmid miniprep kit, or
by cesium chloride purification. The optimal concentration for transfection
generally falls within the range of 0.4–1.0 µg DNA per well of a 24-well
plate, with 0.6 µg as the recommended starting point for optimization.

Cell Density
While we recommend a cell density of 60–80% confluence after 18–24
hours of incubation at the time of transfection for most cell types, the
optimal cell density should be determined specifically for each cell type.

Reagent to DNA Ratio
The optimal reagent to DNA ratio should allow the highest transfection
efficiencies with the lowest level of toxicity. This is usually achieved within
the range of 1–2 µl reagent per µg DNA, with 1.5 µl reagent per µg DNA
the recommended starting point for optimization.

Transfection Incubation Time
The optimal time that the transfection reagent is in contact with the cells
should be determined by testing a range of incubation times from 36–72
hours.
2

SatisFection Transfection Reagent
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SATISFECTION TRANSFECTION REAGENT VOLUME GUIDELINES
The following procedure for the generation of transfectants uses a 24-well
tissue culture plate. The optimal ratio of SatisFection transfection reagent to
DNA must be determined for each plasmid and cell line, however 1.5 µ1
reagent per 1 µg DNA is the recommended starting point for optimization.
Reagent volumes for cells not cultured in 24-well tissue culture plates are
given in Table I. When preparing the transfection mixture, the volume of the
transfection mixture may be scaled up by increasing the components
proportionally to accommodate several transfections.
TABLE I
SatisFection Transfection Reagent use for Various Cell Culture Dish Formats
DNA solution per well

Tissue
culture
dish
format

96-well

Diameter
of the well
(mm)

6.4

Recommended
number of
adherent cells
5
(×10 )

Amount
of DNA
(µg)

0.04–0.1

0.15

Final volume
of DNA
solution
diluted with
serum-free
medium (µl)

7.5

a

Transfection reagent per well
Volume of
transfection
reagent stock
solution (µl)
[1.5:1 ratio
(µl reagent:
µg DNA)]

0.225

Final volume of
transfection
reagent
solution diluted
with serum-free
medium (µl)

7.5

Total
volume of
transfection
mixture plus
medium (µl)

15 µl

48-well

10

0.1–0.3

0.3

15

0.45

15

30 µl

24-well

15

0.27–0.67

0.6

30

0.9

30

60 µl

12-well
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0.6–1.5

1

50

1.5

50

100 µl

6-well

35

1.5–3.7

2

100

3

100

200 µl

35-mm

35

1.5–3.7

2

100

3

100

200 µl

60-mm

60

4.0–11.0

6

300

9

300

600 µl

100-mm

100

12.0–31.0

16

800

24

800

1600 µl
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SatisFection Transfection Reagent
Catalog #204121, 204122, and 204123

QUICK-REFERENCE PROTOCOL–ADHERENT CELLS
4

Seed cells to 2.7–6.7 × 10 cells per well of a 24-well plate and incubate 18–24
hours so that cells are at 60–80% confluency at time of transfection
Prepare transfection mixture
♦

♦

♦

♦

Pipet 30 µl antibiotic-free, serum-free medium (room temperature) into
microcentrifuge tube. Pipet reagent (0.9 µl) into medium, do not touch plastic.
Pipet 30 µl antibiotic-free, serum-free medium (room temperature) into separate
microcentrifuge tube. Add DNA (0.6 µg) to medium.
Add the diluted transfection reagent dropwise to the diluted DNA while gently
vortexing or mixing with the pipet tip.
Incubate transfection mixture 15 minutes at room temperature.
Add the transfection mixture to the cells

♦

Add transfection mixture dropwise and incubate for 36–72 hours under standard
growth conditions.
Perform stable transfection (optional)

♦
♦
♦

36–72 hours after the transfection (above), split cells (1:5 suggested).
After 24 hours, apply selection antibiotics.
Continue selection, replacing medium every 4–7 days until colonies form.
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Appendix C: Protein Extraction and Western Blot

Protein Extraction Protocol
1)

Do all steps on ice or at 4o.

2)

Rinse cells with 1X PBS (1 ml, ice cold)

3)

Add 0.5 ml lysis buffer/well

4)

Incubate on ice for 20 min.

5)

Scrape into microfuge tube

6)

Transfer extract to Dounce homogenizer and homogenize with 10 strokes of Dounce
homogenizer (tight pestle)

7)

Transfer extract back to microfuge tube

8)

Spin in microfuge in cold room for 10 min at max speed

9)

Transfer supernatant to new tube. Save pellet.

Igepal-DOC lysis buffer
1% Igepal
0.4% deoxycholate
10mM Tris pH7.
6.6mM EDTA
-add 1X protease inhibitor cocktail before using lysis buffer
SDS polyacrylamide gel electrophoresis and Western Blot
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Materials
BCA protein assay (Pierce Biotech, cat. #23225)
Mini-PROTEAN II gel apparatus (Biorad)
Costar gel-loading tips (Krackler Scientific, cat. #MN520R-LRS)
Prestained SDS-Page broadrange molecular weight standard (NEB, cat. #P7708S)
Trans-blot Semi-Dry Transfer cell (Biorad)
Immobilon-P membrane (Millipore, cat. #IPV00010)
heat-sealable bags (Kapak, cat. #TRS-95250)
Kodak Biomax light autoradiagraphy film, 13 x 18 cm (Perkin Elmer Life Sciences, cat. #8689358)
Radtape (Diversified Biotech, cat. #RAD-10)
Reagents
TEMED (Sigma)
Tween-20 (Sigma)
Price Chopper non-fat dry milk
Isopropanol (Sigma)
Gel Buffers
Acrylamide solution (30% acrylamide/0.8% bis-acrylamide)
-dissolve 30g acrylamide (FW=71.08), 0.8g bis-acrylamide (FW=154.17) in a total
volume of 100ml water. Filter through 0.2um filter.
4X Running Gel Buffer (1.5M Tris, pH 8.8)
-dissolve 36.3g Tris Base (FW=121.1) in 150ml water. Adjust to pH 8.8. Add water to
total volume of 200ml. Filter through 0.2um filter.
4X Stacking Gel Buffer (0.5M Tris, pH 6.8)
-dissolve 12.1g Tris Base (FW=121.1) in 150ml water. Adjust to pH 6.8. Add water to
total volume of 200ml. Filter through 0.2um filter.
10% SDS
-dissolve 10g SDS (FW=288.38) in a total volume of 100ml water.
10% Ammonium Persulfate
-dissolve 1.0g APS (FW=228.2) in a total volume of 10ml water. Store at -20˚C in 50100ul aliquots.
1M Tris, pH 6.8
-dissolve 12.1g Tris Base (FW=121.1) in 80ml water. Adjust to pH 6.8. Add water to
total volume of 100ml. Filter through 0.2um filter.

6X SDS Sample Buffer (0.375M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6M DTT, 0.06%
bromophenol blue)
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-combine 3.75ml 1M Tris-Cl, pH 6.8, 6ml glycerol, 1.2g SDS (FW=288.38), 0.93g DTT
(FW=154.2), 6mg bromophenol blue. Add water to total volume of 10ml. Store at -20˚C in
0.5ml aliquots.
2X SDS Sample Buffer (0.125M Tris pH 6.8, 4% SDS, 20% glycerol, 0.2M DTT, 0.02%
bromophenol blue)
-combine 2.5ml 4X Tris pH 6.8 (stacking gel buffer), 2ml glycerol, 4ml 10% SDS
(FW=288.38), 0.31g DTT (FW=154.2), 2mg bromophenol blue. Add water to total volume
of 10ml. Store at -20˚C in 0.5ml aliquots.
1X SDS Sample Buffer (0.0625M Tris pH 6.8, 2% SDS, 10% glycerol, 0.1M DTT, 0.01%
bromophenol blue)
5X Electrophoresis Buffer (0.125M Tris, 0.96M glycine, 0.5% SDS)
-dissolve 30.3g Tris Base (FW=121.1), 144.1g glycine (FW=75.07), and 10g SDS
(FW=288.38) in a total volume of 2L water.
1X Electrophoresis Buffer (0.025M Tris, 0.192M glycine, 0.1% SDS)
-add 200ml 5X electrophoresis buffer to 800ml water.
Western Blot Buffers
Transfer Buffer (0.048M Tris, 0.039M glycine, 20% methanol, 0.00375% SDS)
-dissolve 11.64g Tris Base (FW=121.1), 5.86g glycine (FW=75.07) in ~1500ml water.
Add 0.750ml 10% SDS (FW=288.38). Add 400ml methanol. Add water to total volume
of 2L. No pH adjustment necessary.
10X TBST Wash Buffer (0.1M Tris HCl, 1.5M NaCl, 0.5% Tween-20)
-dissolve 31.52g Tris HCl (FW=157.6), 175.32g NaCl (FW=58.44) in ~1900ml water.
Add 10ml
Tween-20. Adjust to pH 7.2. Add water to total volume of 2L.

1X TBST Wash Buffer (0.01M Tris HCl, 0.15M NaCl, 0.05% Tween-20)
-add 100ml 10X TBST to 900ml water.
5% milk Blocking Buffer
-Dissolve 5g milk in a total volume of 100ml 1X TBST.
Method
1. Determine cell number or protein concentration to be loaded onto gels and what volume to
load per well. Note max volumes for different comb configurations.
2. Usually add sample to Tris or PBS and then add sample buffer (2 ul sample + 18 ul PBS + 3.3
ul 6X sample buffer).
3. Sonicate cells briefly on ice to homogenize. Purified protein samples do not need to be
sonicated.
4. Preparing resolving and stacking gels (for BioRad Mini-PROTEAN II): Make sure glass plates
are clean. Use Sparkleen or Alconox powder to clean plates. Rinse with distilled water and then

34
95% EtOH. Wipe dry with KimWipes. Select a comb and spacer (ex. 0.75 mm). Place spacers
in between the inner and outer glass plates. Make sure that the spacers are flush with the plates.
Insert plates into the clamping assembly and tighten screws. Vacuum grease can be used on the
casting stand gaskets to prevent buffer leakage. Snap assembly into the casting stand. Prepare
resolving gel. Pour gel and overlay with 1X Electrophoresis Buffer or isopropanol (use 3.5ml
resolving gel when using 0.75mm spacers and 7.0ml gel for 1.5mm spacers, this will produce a
gel approx. 3.25" x 2"). Look for a division between the overlay and resolving gel, this means
the gel is polymerized. Pour off overlay, use thin strips of Whatman paper to remove any excess.
Pour stacking gel and insert comb. Remove comb when stacking gel is polymerized. Use a
syringe and a 12 gauge needle to wash stacking gel wells. Snap clamp assembly into electrode
assembly. Vacuum grease can be used on electrode assembly gaskets to prevent buffer leakage.
5. Boil samples 5 minutes at 100°C, and then spin tubes at 13,000rpm for ~1min. in RT micro
centrifuge. Load samples using Costar Gel-Loading Tips.
6. Place electrode assembly with loaded samples into an electrophoresis chamber. Fill the
electrode assembly carefully with 1X Electrophoresis Buffer. Fill the electrophoresis chamber
with 1X Electrophoresis Buffer. Run gels at 100V for stacking gel, 100-150V for resolving gel
(can increase to 200V for resolving gel if running on ice).
7. To transfer mini- gels to Immobilon-P membrane using the BioRad Semi-Dry Transfer Cell:
Remove gels from glass plates. Cut stacking gel away and discard. Incubate gels in Transfer
Buffer for 20 - 40 min. Cut out 6 pieces of Whatman paper and 1 piece of Immobilon-P
membrane for each gel that is being transferred. They should be 3.25" x 2". Incubate ImmobilonP membrane in Methanol for ~10 - 20 seconds. Wet Immobilon-P membrane and Whatman
paper in Transfer Buffer for 5 - 10 minutes before assembling the gel sandwich according to the
BioRad Reference Guide. Transfer 1 mini-gel for 15 min. at 15 V, max current. Transfer 2 minigels for 30 min at 15 V, max current. Make sure that pre-stained MW markers transfer to
Immobilon-P membrane.
8. Western Blot:
-Block membrane in 20ml blocking buffer overnight at 4°C or 1h at room temperature on
rocker in a seal-a-meal bag.
-Dilute Ab in blocking buffer (1:1000 for serum or 5ug / 10ml for purified Ab). Incubate
blots with Ab for 1h at rom temperature or overnight at 4°C on rocker in a seal-a-meal
bag.
-Wash blots with 50ml 1X TBST on orbital shaker 3 times, 5 minutes each.
-Dilute HRP conjugated Ab 1:10,000. Incubate blots with secondary Ab for 1h at room
temperature or overnight at 4°C on rocker in a seal-a-meal bag.
-Wash blots with 50ml 1X TBST on orbital shaker 3 times, 5 minutes each.
-Add 5ml chemiluminescent substrate to each blot, incubate for 5 minutes. Place blots in
between transparency film. Push out air bubbles. Develop Western blot. Do a 1 minute
exposure to check signal intensity. Continue with longer or shorter exposures as needed.
(Max. exposure length = 10 min. Min exposure length = 60 sec.)
-For high backgrounds, wash in TBST then re-develop.
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Resolving Gel
7.5% gel (15ml)

10% gel
(15ml)

15% gel
(15ml)

7.5ml

6.25ml

3.75ml

3.75ml

5ml

7.5ml

3.75ml

3.75ml

3.75ml

10% SDS

150ul

150ul

150ul

10% APS

150ul

150ul

150ul

TEMED

20ul

20ul

20ul

Water
30%
acrylamide/
0.8% bisacrylamide
4X Running
Buffer

Running Gel: 7.5, 10, or 15% acrylamide, 0.375M Tris-Cl pH 8.8, 0.1% SDS, 0.33% APS,
0.66% TEMED
Stacking Gel
4% gel (10ml)
Water

6.1ml

30% acrylamide/
0.8% bis-acrylamide

1.3ml

4X Stacking Buffer

2.5ml

10% SDS

100ul

10% APS

100ul

TEMED

20ul

Stacking Gel: 4% acrylamide, 0.125M Tris-Cl pH 6.8, 0.1% SDS, 0.05%APS, 0.2%
TEMED
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